Literature DB >> 18649105

The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients.

Yong Chen1, Huichen Xu, Yuyan Li, Dan Wang, Junnan Li, Jizhao Yuan, Zhiqing Liang.   

Abstract

OBJECTIVES: Cervical carcinoma is likely to become one of the most important indications for laparoscopic radical surgery. The laparoscopic technique combines the benefits of a minimally invasive approach with established surgical principles. In our institution, the laparoscopic radical hysterectomy and transperitoneal approach for lymphadenectomy have become the standard techniques for invasive cervical cancer. We report the indications, techniques, results, and oncological outcome in a single center experience.
METHODS: Between February 2001 and June 2007 we performed laparoscopic radical hysterectomies for cervical cancer in 295 patients. Their initial techniques, operation data, complications, postoperative course, oncological outcome, and survival were evaluated.
RESULTS: Out of 295 procedures, 290 were successful. Para-aortic lymphadenectomy was performed in 156 patients (52.9%), and pelvic lymphadenectomy was performed in all 295 patients. The median blood loss was 230 mL (range, 50-1200 mL). The mean operation time was 162 min (range, 110-350), which included the learning curves of 3 surgeons. In 5 cases (1.7%), conversion to open surgery was necessary due to bleeding (3 cases), bowel injury (1 case), and hypercapnia (1 case). Other major intraoperative injuries occurred in 12 patients (4.1%). Positive lymph nodes were detected in 80 cases (27.1%), lymphovascular space invasion in 54 cases (18.3%), and surgical margins were negative for tumor in all patients. The mean hospital stay was 10.3 days. Postoperative complications occurred in 10.8% patients, ureterovaginal fistula in 5 cases, vesicovaginal fistula in 4, ureterostenosis in 3 cases, deep venous thrombosis in 9 cases, lymphocyst in 4 cases, lymphedema in 5 cases, and 1 case with trocar insertion site metastasis. Other medical problems included 47 cases (15.9%) of bladder dysfunction and 62 cases (21.0%) of rectum dysfunction or constipation. The median follow-up was 36.45 months (range, 8-76 months). Recurrences or metastasis occurred in 48 patients (16.3%). Of these patients, 43 (14.6%) have died of their disease, and 5 (1.7%) are alive with disease. The overall disease-free survival was 95.2% for Ia, 96.2% for Ib, 84.5% for IIa, 79.4% for IIb, 66.7% for IIIa, and 60.0% for IIIb.
CONCLUSION: Laparoscopic radical hysterectomy is a routine, effective treatment for patients with Ia2-IIb cervical carcinoma. With more experience it is envisaged that IIb stage patients can be managed safely offering all the benefits of minimal surgery to the patients. Although no long-term follow-up is available, our follow-up data for up to 76 months confirm the effectiveness of laparoscopic radical hysterectomy in terms of surgical principles and oncological outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18649105     DOI: 10.1245/s10434-008-0063-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Urologic complications of laparoscopic radical hysterectomy and lymphadenectomy.

Authors:  Jong Ha Hwang; Myong Cheol Lim; Jae Young Joung; Sang-Soo Seo; Sokbom Kang; Ho Kyung Seo; Jinsoo Chung; Sang-Yoon Park
Journal:  Int Urogynecol J       Date:  2012-04-25       Impact factor: 2.894

2.  Recent advances of robotic surgery and single port laparoscopy in gynecologic oncology.

Authors:  Yong Wook Jung; Sang Wun Kim; Young Tae Kim
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

3.  Adjuvant chemoradiation after laparoscopically assisted vaginal radical hysterectomy (LARVH) in patients with cervical cancer: oncologic outcome and morbidity.

Authors:  Arne Gruen; Thabea Musik; Christhardt Köhler; Jürgen Füller; Thomas Wendt; Carmen Stromberger; Volker Budach; Achim Schneider; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

4.  Systematic review of urological injury during caesarean section and hysterectomy.

Authors:  Gavin Wei; Frances Harley; Michael O'Callaghan; James Adshead; Derek Hennessey; Ned Kinnear
Journal:  Int Urogynecol J       Date:  2022-10-17       Impact factor: 1.932

Review 5.  Assessing risk of venous thromboembolism in the patient with cancer.

Authors:  Alok A Khorana; Gregory C Connolly
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

6.  Feasibility, safety, and cost outcomes of laparoscopic management of early endometrial and cervical malignancy.

Authors:  Georgios E Hilaris; Thomas Tsoubis; Vasilios Konstantopoulos; Kitty Pavlakis
Journal:  JSLS       Date:  2009 Oct-Dec       Impact factor: 2.172

7.  Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept.

Authors:  Lucia M A Crane; George Themelis; Rick G Pleijhuis; Niels J Harlaar; Athanasios Sarantopoulos; Henriette J G Arts; Ate G J van der Zee; Vasilis Ntziachristos; Ntziachristos Vasilis; Gooitzen M van Dam
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

8.  Vaginal-assisted laparoscopic radical hysterectomy: rationale, technique, results.

Authors:  Elisabeth Gottschalk; Malgorzata Lanowska; Vito Chiantera; Simone Marnitz; Achim Schneider; Verena Brink-Spalink; Kati Hasenbein; Christhardt Koehler
Journal:  JSLS       Date:  2011 Oct-Dec       Impact factor: 2.172

9.  Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer.

Authors:  Brandon M Barney; Ivy A Petersen; Sean C Dowdy; Jamie N Bakkum-Gamez; Kristi A Klein; Michael G Haddock
Journal:  Radiat Oncol       Date:  2013-04-08       Impact factor: 3.481

10.  Incisional site metastasis in a patient with cervical carcinoma: a case report and review of the literature.

Authors:  C Iavazzo; K Madhuri; A Tailor; S Butler-Manuel
Journal:  Case Rep Obstet Gynecol       Date:  2012-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.